Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06445361

Prevalence of NAFLD in T1DM Patients

To determine the prevalence of NAFLD in T1DM patients.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

NAFLD Autoimmune Diseases Diabetes Mellitus Diabetes Mellitus, Type 1 Digestive System Diseases Endocrine System Diseases Fatty Liver Fatty Liver, Nonalcoholic Glucose Metabolism Disorders Immune System Diseases Liver Diseases Metabolic Diseases Non-alcoholic Fatty Liver Disease Nutritional and Metabolic Diseases Type 1 Diabetes

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ziekenhuis Oost-Limburg

Genk, Limburg, 3600, Belgium

Location status: Recruiting

Location contact

Leen Heyens, MsC

CONTACT

[email protected]

089 21 20 55 ext. +32

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • T1DM
  • ≥ 18 years of age
  • Written informed consent obtained

Exclusion criteria

  • Excessive alcohol use
  • Exclusion of other causes of liver disease and secondary causes of liver steatosis

Treatment and study plan

FibroScan

Diagnostic Test

Performance of a FibroScan measurement to determine steatosis and fibrosis.

Primary outcomes

  1. Prevalence of NAFLD in T1DM

    Time frame: During the intervention

    To determine the prevalence of steatosis in a cohort of T1DM patients followed at the Departments of Endocrinology in ZOL by means of the FibroScan® device with controlled attenuation parameter (CAP) measurements.

  2. Prevalence of fibrosis in T1DM

    Time frame: During the intervention

    To determine the prevalence of fibrosis in a cohort of T1DM patients followed at the Departments of Endocrinology in ZOL by means of the FibroScan® device with vibration controlled attenuation parameter (VCTE) measurements.

Study contacts

Contact information is provided by the study sponsor or research team.

Leen Heyens, MsC

CONTACT

[email protected]

089 21 20 55 ext. +32

Sponsors and collaborators

Lead sponsor

Ziekenhuis Oost-Limburg

Other

Registry information

Official study title

The Prevalence of Non-Alcoholic Fatty Liver Disease in Type 1 Diabetes Mellitus Patients Followed at Ziekenhuis Oost-Limburg, Genk, Belgium

Acronym: PAD1ZOL

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Jun 6, 2024
Registry last updated
Jul 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.